+357 96 030922
info@marketpublishers.com

Global Asthma Therapeutics Market Size study, by Drug Class, Treatment Type, Route of Administration (Inhaled, Oral, Injectable), Distribution Channel, End-use (Hospitals & clinics, ASCs, Homecare settings) and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G1C6512C3F0CEN.html
Date: May 2025
Pages: 285
Price: US$ 3,750.00 (Single User License)
ID: G1C6512C3F0CEN

Abstracts

Global Asthma Therapeutics Market is valued approximately at USD 25.7 billion in 2023 and is anticipated to grow with a steady compound annual growth rate of more than 4.40% over the forecast period 2024–2032. Asthma, a chronic inflammatory disorder of the airways characterized by variable respiratory symptoms and airflow obstruction, continues to afflict millions worldwide. As the prevalence of environmental allergens, urban pollution, and genetic predispositions climbs, the demand for advanced and diversified therapeutic options is intensifying. Asthma therapeutics have progressed well beyond traditional bronchodilators, now encompassing biologics, anti-inflammatory agents, and targeted monoclonal antibodies tailored to phenotype-specific treatments—ushering in an era of personalized respiratory care.

Growing recognition of asthma's heterogeneity and the expansion of asthma management guidelines have opened avenues for innovation in both maintenance and acute treatments. Robust R&D pipelines, fueled by increasing healthcare expenditure and strategic investments by key pharmaceutical giants, are driving the development of long-acting agents and next-generation biologics. Additionally, the expansion of mobile health platforms and smart inhaler devices are bridging gaps in medication adherence and monitoring, significantly contributing to therapeutic outcomes. However, reimbursement disparities and cost-intensive biologic therapies continue to challenge equitable access, particularly in low-resource settings.

The asthma therapeutics market is being buoyed by a mix of lifestyle factors and clinical

demand. Urbanization, sedentary habits, and rising exposure to allergens have led to a spike in asthma diagnoses globally. Furthermore, the COVID-19 pandemic underscored the criticality of robust respiratory health, driving awareness and early intervention behaviors. Inhaled therapies remain the cornerstone of asthma management, but injectable biologics are rapidly gaining traction among patients with moderate-to-severe asthma unresponsive to conventional treatments. With leading players increasingly emphasizing patient-centric care models and integrated health platforms, the market is shifting toward a more adaptive and holistic framework.

Geographically, North America commands the lion's share of the market, supported by a strong reimbursement network, clinical trial activity, and widespread asthma awareness programs. The U.S. leads this regional momentum through active FDA approvals and widespread biologic usage. Europe also maintains a sizable presence, particularly in nations with robust healthcare systems such as Germany, France, and the UK. Asia Pacific, however, is projected to register the fastest CAGR through 2032, driven by rising healthcare infrastructure investments, growing middle-class populations, and an alarming rise in pediatric asthma cases. In India and China, increasing availability of generic inhalers and government-led air quality interventions are helping boost access to treatments.

Meanwhile, Latin America and the Middle East & Africa are emerging as pivotal contributors to global market expansion. Regional growth is being supported by targeted healthcare funding, increased chronic disease screening programs, and improving pharmaceutical logistics networks. Countries like Brazil, Mexico, South Africa, and Saudi Arabia are prioritizing non-communicable disease management in national health policies, creating fertile ground for the expansion of asthma therapeutics. Furthermore, global market participants are increasingly forming local partnerships and licensing agreements to capitalize on untapped potential in these underserved yet growing economies.

Major market player included in this report are:

AstraZeneca plc

GlaxoSmithKline plc

Sanofi S.A.

Boehringer Ingelheim International GmbH

+357 96 030922
info@marketpublishers.com

Novartis AG

Merck & Co., Inc.

Cipla Ltd.

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Johnson & Johnson

Amgen Inc.

Viatris Inc.

Chiesi Farmaceutici S.p.A.

Roche Holding AG

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Corticosteroids

Bronchodilators

Leukotriene Modifiers

Monoclonal Antibodies

Others

+357 96 030922
info@marketpublishers.com

By Treatment Type

- Long-Term Control Medications
- Quick-Relief Medications
- Others

By Route of Administration

- Inhaled
- Oral
- Injectable

By Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

By End-use

- Hospitals & Clinics
- Ambulatory Surgical Centers (ASCs)
- Homecare Settings

By Region:

North America

+357 96 030922
info@marketpublishers.com

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

+357 96 030922
info@marketpublishers.com

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

+357 96 030922
info@marketpublishers.com

Demand side and supply side analysis of the market.

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 1. GLOBAL ASTHMA THERAPEUTICS MARKET EXECUTIVE SUMMARY

1.1. Global Asthma Therapeutics Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
  1.3.1. By Drug Class
  1.3.2. By Treatment Type
  1.3.3. By Route of Administration
  1.3.4. By Distribution Channel
  1.3.5. By End-use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL ASTHMA THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
  2.3.1. Inclusion & Exclusion
  2.3.2. Limitations
  2.3.3. Supply Side Analysis
    2.3.3.1. Availability
    2.3.3.2. Infrastructure
    2.3.3.3. Regulatory Environment
    2.3.3.4. Market Competition
    2.3.3.5. Economic Viability (Patient’s Perspective)
  2.3.4. Demand Side Analysis
    2.3.4.1. Regulatory Frameworks
    2.3.4.2. Technological Advancements
    2.3.4.3. Environmental Considerations
    2.3.4.4. Patient Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
– Historical year – 2022

+357 96 030922
info@marketpublishers.com

– Base year – 2023
– Forecast period – 2024 to 2032
2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL ASTHMA THERAPEUTICS MARKET DYNAMICS

3.1. Market Drivers
  3.1.1. Rising Prevalence of Allergens and Pollution
  3.1.2. Expansion of Biologic and Targeted Therapies
  3.1.3. Integration of Digital Health and Smart Inhalers
3.2. Market Challenges
  3.2.1. High Cost of Biologics and Reimbursement Constraints
  3.2.2. Patient Non-adherence and Device Misuse
  3.2.3. Regulatory Hurdles for Novel Therapeutics
3.3. Market Opportunities
  3.3.1. Emergence of Biosimilars and Generics
  3.3.2. Growth in Homecare and Telehealth Services
  3.3.3. Penetration into Emerging Markets

CHAPTER 4. GLOBAL ASTHMA THERAPEUTICS MARKET INDUSTRY ANALYSIS

4.1. Porter’s Five Forces Model
  4.1.1. Bargaining Power of Suppliers
  4.1.2. Bargaining Power of Buyers
  4.1.3. Threat of New Entrants
  4.1.4. Threat of Substitutes
  4.1.5. Competitive Rivalry
  4.1.6. Futuristic Approach to Porter’s Model
  4.1.7. Impact Analysis
4.2. PESTEL Analysis
  4.2.1. Political
  4.2.2. Economic
  4.2.3. Social
  4.2.4. Technological
  4.2.5. Environmental
  4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends

4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE & FORECASTS BY DRUG CLASS 2022–2032

5.1. Segment Dashboard
5.2. Global Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  5.2.1. Corticosteroids
  5.2.2. Bronchodilators
  5.2.3. Leukotriene Modifiers
  5.2.4. Monoclonal Antibodies
  5.2.5. Others

CHAPTER 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE & FORECASTS BY TREATMENT TYPE 2022–2032

6.1. Segment Dashboard
6.2. Global Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  6.2.1. Long-Term Control Medications
  6.2.2. Quick-Relief Medications
  6.2.3. Others

CHAPTER 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022–2032

7.1. Segment Dashboard
7.2. Global Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  7.2.1. Inhaled
  7.2.2. Oral
  7.2.3. Injectable

CHAPTER 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL 2022–2032

8.1. Segment Dashboard
8.2. Global Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD

+357 96 030922
info@marketpublishers.com

Billion)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies

CHAPTER 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE & FORECASTS BY END-USE 2022–2032

9.1. Segment Dashboard
9.2. Global Market: End-use Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Hospitals & Clinics
9.2.2. Ambulatory Surgical Centers (ASCs)
9.2.3. Homecare Settings

CHAPTER 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022–2032

10.1. North America Market
10.1.1. U.S. Market
10.1.2. Canada Market
10.2. Europe Market
10.2.1. UK Market
10.2.2. Germany Market
10.2.3. France Market
10.2.4. Spain Market
10.2.5. Italy Market
10.2.6. Rest of Europe
10.3. Asia-Pacific Market
10.3.1. China Market
10.3.2. India Market
10.3.3. Japan Market
10.3.4. Australia Market
10.3.5. South Korea Market
10.3.6. Rest of Asia-Pacific
10.4. Latin America Market
10.4.1. Brazil Market
10.4.2. Mexico Market
10.4.3. Rest of Latin America
10.5. Middle East & Africa Market

+357 96 030922
info@marketpublishers.com

10.5.1. Saudi Arabia Market
10.5.2. South Africa Market
10.5.3. Rest of Middle East & Africa

CHAPTER 11. COMPETITIVE INTELLIGENCE

11.1. Key Company SWOT Analysis
11.1.1. AstraZeneca plc
11.1.2. GlaxoSmithKline plc
11.1.3. Sanofi S.A.
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. AstraZeneca plc
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. GlaxoSmithKline plc
11.3.3. Sanofi S.A.
11.3.4. Boehringer Ingelheim International GmbH
11.3.5. Novartis AG
11.3.6. Merck & Co., Inc.
11.3.7. Cipla Ltd.
11.3.8. Pfizer Inc.
11.3.9. Teva Pharmaceutical Industries Ltd.
11.3.10. Mylan N.V.
11.3.11. Johnson & Johnson
11.3.12. Amgen Inc.
11.3.13. Viatris Inc.
11.3.14. Chiesi Farmaceutici S.p.A.
11.3.15. Roche Holding AG

CHAPTER 12. RESEARCH PROCESS

12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation

+357 96 030922
info@marketpublishers.com

12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Asthma Therapeutics Market Size study, by Drug Class, Treatment Type, Route of Administration (Inhaled, Oral, Injectable), Distribution Channel, End-use (Hospitals & clinics, ASCs, Homecare settings) and Regional Forecasts 2022-2032

Product link: https://marketpublishers.com/r/G1C6512C3F0CEN.html

Price: US$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G1C6512C3F0CEN.html